Lixisenatide slows motor disability progression in early PD
![Close Up Of Senior Man Suffering With Parkinsons Diesease](https://www.medwirenews.com/wp-content/uploads/2024/05/iStock-647711856_man_Parkinsons-disease_resized.jpg)
The glucagon-like peptide-1 receptor agonist lixisenatide slows motor disability progression in patients with early Parkinson’s disease, suggest findings from the LIXIPARK trial.
The glucagon-like peptide-1 receptor agonist lixisenatide slows motor disability progression in patients with early Parkinson’s disease, suggest findings from the LIXIPARK trial.